The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) in the ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...

Following this approval, Sarclisa is the first anti-CD38 therapy in combination with VRd for treating transplant-ineligible NDMM patients. A regulatory filing is currently under review in the EU ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Binod Dhakal, MD, MS, discusses how the efficacy results observed with ciltacabtagene autoleucel in the CARTITUDE-4 trial compare with other therapies that are used for the treatment of ...

Other innovative medicines like Nexviazyme, Rezurock, and Sarclisa continue to perform well and are contributing to a total of EUR1.4 billion in sales for this quarter alone. These results show ...

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

They were driven by new pharmaceutical launches (up 67.1% to €727 million), including Altuviiio, used to treat haemophilia, Tzield - for type 1 diabetes -, Sarclisa (multiple myeloma) and Rezurock, ...

It also vowed to keep Opella's headquarters in France, the same source added. Read also: USFDA nod to Sanofi Sarclisa in combo with bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple ...